Search | Science Publications

Research ArticleOpen accessIn the author namesPharmacodynamic Comparison of the Carbapenems Against E. coli and Klebsiella spp. Containing Extended spectrum β-lactamasesKathryn J. Eagye, Joseph L. Kuti, David P. NicolauCarbapenems are the treatment of choice for extended-spectrum β-lactamases (ESBLs). Ertapenem is a new member of the carbapenem class, and is often grouped with imipenem and meropenem as a recommended treatment for ESBLs. However, new in vitro data question ertapenem’s inclusion as a first line treatment for these bacteria, suggesting that ertapenem has a lower likelihood of obtaining appropriate pharmacodynamic … …American Journal of Infectious Diseases, Vol. 1, Issue 3 · 30 Sep 2005 · 6,890 accessesView PDF Cite

1 article for “David P. Nicolau”